Jessilin Quint
Optometrist · Chicago, ILNPI 1841603867
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Alcon at 41.8% of the total. 2025 is the largest year on record at $143,022, more than ten times the $5,390 reported in 2019. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 597 payments — averaging $613.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$153K
- AbbVie$99K
- Bausch & Lomb Americas Inc.$82K
- Alcon Research LLC$17K
- Dompe US, Inc.$7K
- Tarsus Pharmaceuticals, Inc.$3K
- plus $4K from 15 others
Across 5 payments — averaging $2630.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tarsus Pharmaceuticals, Inc.$13K
What the payments were for
- Consulting fees$183,12650%
- Speaking & faculty fees$138,32838%
- Travel & lodging$30,5078%
- Food & beverage$14,5124%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 232 | $153,236 |
| AbbVie(2 entities) | 175 | $99,433 |
| Bausch & Lomb Americas Inc. | 90 | $82,439 |
| Alcon Research LLC | 10 | $16,710 |
| Dompe US, Inc. | 9 | $6,804 |
| Tarsus Pharmaceuticals, Inc. | 19 | $3,412 |
| Oyster Point Pharma, Inc. | 13 | $1,452 |
| Sun Pharmaceutical Industries Inc. | 5 | $1,446 |
| Carl Zeiss Meditec USA, Inc. | 7 | $291 |
| Johnson & Johnson Vision Care, Inc. | 7 | $235 |
| Sight Sciences, Inc. | 3 | $215 |
| Biotissue Holdings Inc. | 8 | $209 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $175 |
| Novartis | 5 | $94 |
| Coopervision Inc. | 2 | $94 |
| Astellas Pharma Global Development | 1 | $94 |
| Harrow Eye, LLC | 1 | $69 |
| Shire North American Group Inc | 1 | $32 |
| LKC Technologies, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOTAL30$78,053
- VUITY$78,016
- Precision7$70,729
- DAILIES TOTAL1$70,680
- MIEBO$65,833
- XIIDRA$60,183
- Precision 1$56,021
- Precision 7$13,383
- TRYPTYR$9,604
- Oxervate$6,669
- Systane$4,278
- INFUSE$3,269
- Dailies Aqua Comfort Plus$2,438
- RESTASIS$1,844
- DURYSTA$1,575
- XELPROS$1,301
- DAILIES$1,300
- RESTASIS MULTIDOSE$1,290
- TYRVAYA$960
- XDEMVY$900
How this compares
$366,492 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $738,558 |
| XdemvyLotilaner | 75 | $143,846 |
| RestasisCyclosporine | 48 | $76,147 |
| MieboPerfluorohexyloctane/Pf | 74 | $56,280 |
| XiidraLifitegrast | 42 | $44,748 |
| LumiganBimatoprost | 24 | $12,475 |
| Cyclosporine | 12 | $5,356 |
| Latanoprost | 86 | $1,486 |
| Prednisolone Acetate | 30 | $1,093 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $322 |
| Timolol Maleate | 21 | $259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $6,804 | $738,55813 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $3,412 | $143,84675 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $82,439 | $101,028116 claims |
| AbbVieRestasis, Lumigan | $99,433 | $88,62272 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.
Other optometrist in Chicago
- Pamela LoweChicago$447K
- Michael ChaglasianChicago$367K
- Jullian CerasuoloChicago$329K
- Jennifer HarthanChicago$84K
- Neil HodurChicago$67K
- James SementilliChicago$25K
- Lindsay SicksChicago$23K
- Emma LoyfmanChicago$23K
- Michelle ManChicago$20K
- Vincent BrandysChicago$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.